A detailed history of Green Alpha Advisors, LLC transactions in Ab Cellera Biologics Inc. stock. As of the latest transaction made, Green Alpha Advisors, LLC holds 48,515 shares of ABCL stock, worth $143,119. This represents 0.1% of its overall portfolio holdings.

Number of Shares
48,515
Previous 24,709 96.35%
Holding current value
$143,119
Previous $73,000 71.23%
% of portfolio
0.1%
Previous 0.06%

Shares

13 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Oct 07, 2024

BUY
$2.39 - $3.49 $56,896 - $83,082
23,806 Added 96.35%
48,515 $125,000
Q2 2024

Aug 13, 2024

SELL
$2.73 - $4.73 $9,931 - $17,207
-3,638 Reduced 12.83%
24,709 $73,000
Q1 2024

Apr 09, 2024

BUY
$4.29 - $5.97 $2,230 - $3,104
520 Added 1.87%
28,347 $128,000
Q4 2023

Jan 04, 2024

SELL
$3.91 - $5.93 $45,109 - $68,414
-11,537 Reduced 29.31%
27,827 $158,000
Q3 2023

Oct 10, 2023

SELL
$4.6 - $7.95 $69,234 - $119,655
-15,051 Reduced 27.66%
39,364 $181,000
Q2 2023

Jul 06, 2023

BUY
$5.66 - $7.59 $37,763 - $50,640
6,672 Added 13.97%
54,415 $351,000
Q1 2023

Apr 06, 2023

SELL
$7.31 - $11.18 $6,944 - $10,621
-950 Reduced 1.95%
47,743 $359,000
Q4 2022

Jan 12, 2023

SELL
$9.48 - $14.52 $4,275 - $6,548
-451 Reduced 0.92%
48,693 $0
Q3 2022

Oct 14, 2022

SELL
$9.2 - $13.68 $4,112 - $6,114
-447 Reduced 0.9%
49,144 $486,000
Q2 2022

Jul 08, 2022

BUY
$5.72 - $10.65 $89,106 - $165,905
15,578 Added 45.8%
49,591 $528,000
Q1 2022

Apr 19, 2022

BUY
$7.46 - $14.14 $43,611 - $82,662
5,846 Added 20.75%
34,013 $332,000
Q4 2021

Jan 12, 2022

BUY
$12.99 - $17.73 $51,687 - $70,547
3,979 Added 16.45%
28,167 $403,000
Q3 2021

Oct 12, 2021

BUY
$14.85 - $21.34 $359,191 - $516,171
24,188 New
24,188 $485,000

Others Institutions Holding ABCL

About AbCellera Biologics Inc.


  • Ticker ABCL
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 285,139,008
  • Market Cap $841M
  • Description
  • AbCellera Biologics Inc. develops antibody discovery platform. Its full-stack, artificial intelligence-powered antibody discovery platform searches and analyzes the database of natural immune systems to find antibodies that could be developed as drugs. As of December 31, 2021, the company had 156 discovery programs that are either completed, in ...
More about ABCL
Track This Portfolio

Track Green Alpha Advisors, LLC Portfolio

Follow Green Alpha Advisors, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Green Alpha Advisors, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Green Alpha Advisors, LLC with notifications on news.